JP2020036595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020036595A5 JP2020036595A5 JP2019195331A JP2019195331A JP2020036595A5 JP 2020036595 A5 JP2020036595 A5 JP 2020036595A5 JP 2019195331 A JP2019195331 A JP 2019195331A JP 2019195331 A JP2019195331 A JP 2019195331A JP 2020036595 A5 JP2020036595 A5 JP 2020036595A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- polypeptide
- cells
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004748 cultured cell Anatomy 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000235058 Komagataella pastoris Species 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443281P | 2017-01-06 | 2017-01-06 | |
| US62/443,281 | 2017-01-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Division JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020036595A JP2020036595A (ja) | 2020-03-12 |
| JP2020036595A5 true JP2020036595A5 (enExample) | 2021-07-26 |
| JP7153626B2 JP7153626B2 (ja) | 2022-10-14 |
Family
ID=62791389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Active JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
| JP2019195331A Active JP7153626B2 (ja) | 2017-01-06 | 2019-10-28 | 抗ヒト４－１ｂｂ抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Active JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10174122B2 (enExample) |
| EP (2) | EP3523332B1 (enExample) |
| JP (2) | JP6609724B1 (enExample) |
| KR (2) | KR102089072B1 (enExample) |
| CN (2) | CN112210010B (enExample) |
| AU (3) | AU2018206015B2 (enExample) |
| BR (1) | BR112019007714B1 (enExample) |
| CA (1) | CA3039772C (enExample) |
| ES (1) | ES2905890T3 (enExample) |
| MX (1) | MX374810B (enExample) |
| RU (1) | RU2725811C1 (enExample) |
| SG (2) | SG10201914064QA (enExample) |
| WO (1) | WO2018127787A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| AU2018206015B2 (en) * | 2017-01-06 | 2019-05-30 | Eutilex Co., Ltd. | Anti-human 4-1 BB antibodies and use thereof |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| AU2019312200B2 (en) | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| BR112021004698A2 (pt) * | 2018-09-12 | 2021-06-01 | Eucure (Beijing) Biopharma Co., Ltd | anticorpos anti-tnfrsf9 e usos dos mesmos |
| WO2020077635A1 (zh) * | 2018-10-19 | 2020-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
| BR112021010402A2 (pt) | 2018-11-30 | 2021-08-24 | Abl Bio Inc. | Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos |
| CN113382752B (zh) | 2019-01-02 | 2025-03-04 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| WO2020257681A1 (en) * | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
| WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| WO2021170067A1 (zh) * | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
| US20230143003A1 (en) * | 2020-03-13 | 2023-05-11 | Julius-Maximilians-Universität Würzburg | Affinity matured and humanized binding domains targeting ror2 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| US20230250188A1 (en) * | 2020-06-11 | 2023-08-10 | National University Corporation Kochi University | Humanized Anti-GPC-1 Antibody |
| KR20230042524A (ko) | 2020-08-07 | 2023-03-28 | 주식회사 유틸렉스 | 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도 |
| CN114075287B (zh) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
| JP2023541853A (ja) * | 2020-09-08 | 2023-10-04 | ユーティレックス カンパニー リミテッド | Ｐｄ－１ポリペプチド変異体 |
| CN114195894B (zh) * | 2020-09-17 | 2025-02-25 | 普米斯生物技术(珠海)有限公司 | 一种靶向4-1bb的抗体及其应用 |
| EP4276111A4 (en) * | 2021-01-08 | 2025-04-30 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody |
| WO2022148410A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| EP4274852A4 (en) * | 2021-01-11 | 2025-02-26 | Eutilex Co., Ltd. | BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF |
| AU2022336889A1 (en) * | 2021-08-31 | 2024-03-14 | LaNova Medicines Limited | Anti-4-1bb nanobodies |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025106539A1 (en) * | 2023-11-14 | 2025-05-22 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6090381A (en) | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| EP1029550A4 (en) | 1997-11-10 | 2001-09-26 | Mochida Pharm Co Ltd | PREVENTIVE AND THERAPEUTIC DRUGS FOR DIFFUSED PULMONARY CONDITIONS |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| CA2386341A1 (en) | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Heteroclitic analogs and related methods |
| EP1235848A4 (en) | 1999-12-10 | 2005-02-09 | Epimmune Inc | INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS |
| SI1311542T1 (sl) | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| KR100468321B1 (ko) * | 2001-02-08 | 2005-01-27 | 학교법인 울산공업학원 | 종양 및 에이즈치료용 폴리펩타이드 |
| WO2002072013A2 (en) | 2001-03-09 | 2002-09-19 | Baylor Research Institute | Method of treating malignancies through induction of blood immune responses |
| ATE435655T1 (de) | 2001-10-09 | 2009-07-15 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| KR100500286B1 (ko) | 2002-07-02 | 2005-07-11 | 현대모비스 주식회사 | 자동차용 램프 스위치 장치 |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
| DK1623017T3 (da) | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
| US20050011582A1 (en) | 2003-06-06 | 2005-01-20 | Haug Jeffrey S. | Fluid delivery system for a flow cytometer |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| PT2016414E (pt) | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| KR100882445B1 (ko) | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| KR101103603B1 (ko) | 2008-07-25 | 2012-01-09 | 국립암센터 | 4-1ｂｂｌ 펜타머 단백질을 이용한 항원 특이적 ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| KR20100043130A (ko) | 2008-10-18 | 2010-04-28 | 울산대학교 산학협력단 | 세포 활성 조성물 |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| TW201613635A (en) * | 2014-02-04 | 2016-04-16 | Pfizer | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| US11505605B2 (en) * | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| CN106413751A (zh) | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3258959A4 (en) * | 2015-02-22 | 2018-10-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
| MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| WO2017205745A1 (en) * | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| AU2018206015B2 (en) | 2017-01-06 | 2019-05-30 | Eutilex Co., Ltd. | Anti-human 4-1 BB antibodies and use thereof |
| SG11202005272SA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
| CN113302285A (zh) | 2018-08-10 | 2021-08-24 | 优特力克斯有限公司 | 癌抗原特异性cd8+t细胞的制备及冷冻保存方法 |
-
2018
- 2018-01-05 AU AU2018206015A patent/AU2018206015B2/en active Active
- 2018-01-05 RU RU2019116731A patent/RU2725811C1/ru active
- 2018-01-05 KR KR1020197015730A patent/KR102089072B1/ko active Active
- 2018-01-05 SG SG10201914064QA patent/SG10201914064QA/en unknown
- 2018-01-05 JP JP2019517981A patent/JP6609724B1/ja active Active
- 2018-01-05 EP EP18736336.1A patent/EP3523332B1/en active Active
- 2018-01-05 US US15/863,526 patent/US10174122B2/en active Active
- 2018-01-05 ES ES18736336T patent/ES2905890T3/es active Active
- 2018-01-05 CN CN202011039658.5A patent/CN112210010B/zh active Active
- 2018-01-05 MX MX2019004692A patent/MX374810B/es active IP Right Grant
- 2018-01-05 EP EP21211128.0A patent/EP4032911A1/en active Pending
- 2018-01-05 WO PCT/IB2018/000043 patent/WO2018127787A1/en not_active Ceased
- 2018-01-05 CN CN201880005123.0A patent/CN110392696B/zh active Active
- 2018-01-05 CA CA3039772A patent/CA3039772C/en active Active
- 2018-01-05 SG SG11201903021WA patent/SG11201903021WA/en unknown
- 2018-01-05 BR BR112019007714-6A patent/BR112019007714B1/pt active IP Right Grant
- 2018-01-05 KR KR1020207006944A patent/KR102427192B1/ko active Active
- 2018-11-14 US US16/191,381 patent/US10919972B2/en active Active
-
2019
- 2019-07-05 AU AU2019204847A patent/AU2019204847B2/en active Active
- 2019-10-28 JP JP2019195331A patent/JP7153626B2/ja active Active
-
2020
- 2020-02-13 US US16/790,299 patent/US10774151B2/en active Active
-
2021
- 2021-01-26 US US17/158,474 patent/US11859004B2/en active Active
- 2021-04-22 AU AU2021202474A patent/AU2021202474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020036595A5 (enExample) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| US9758583B2 (en) | Anti-CTLA-4 antibodies | |
| CA2973332C (en) | Anti-pd-l1 antibodies | |
| RU2715628C2 (ru) | Антитела к pd-1 | |
| CA3015938A1 (en) | Anti-lag-3 antibodies | |
| WO2018036473A1 (zh) | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 | |
| CN118852460A (zh) | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) | |
| JP2013529084A5 (enExample) | ||
| CN106699891A (zh) | 一种抗pd‑l1 抗体、其药物组合物及其用途 | |
| TW202136304A (zh) | Ｉｌｔ３結合劑及其使用方法 | |
| JP2022044795A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| JP2018521959A5 (enExample) | ||
| JP2020528765A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| Peterson | Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins | |
| US20250376531A9 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| US20240067741A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| CN118108845B (zh) | 一种靶向B7-H3的CAR-γδT细胞的制备方法及应用 | |
| CN119638838B (zh) | 一种抗程序化死亡分子1的纳米抗体及其应用 | |
| CN110760002A (zh) | 人源化抗人ctla4单克隆抗体及其制备方法和用途 | |
| CN108546299B (zh) | 解除pd-1对机体免疫抑制的靶向分子 | |
| WO2024238287A1 (en) | Dual blocking and chimeric cytokine receptor |